Breaking: Johnson & Johnson (JNJ) Q4 results lead stock higher in Tuesday's pre-market
- Johnson & Johnson earnings per share (EPS) $1.86 versus $1.82 analyst expectations.
- Quarterly revenue up over 8%, beating analysts expectations.
- Further commentary on earnings call later on Tuesday.

Shares in Johnson & Johnson (JNJ) are trading nearly 2% higher in Tuesdays pre-market session as Q4 results boosted investors’ optimism. JNJ will host a conference call later on Tuesday (0830 EST), where investors will hope to get further information on JNJ covid-19 vaccine developments.
The author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
This article is for information purposes only. The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice. It is important to perform your own research before making any investment and take independent advice from a registered investment advisor.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to accuracy, completeness, or the suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. The author will not be held responsible for information that is found at the end of links posted on this page.
Premium
You have reached your limit of 3 free articles for this month.
Start your subscription and get access to all our original articles.
Author

Ivan Brian
FXStreet
Ivan Brian started his career with AIB Bank in corporate finance and then worked for seven years at Baxter. He started as a macro analyst before becoming Head of Research and then CFO.

















